Another Dendreon Earnings Disaster?
Dendreon, a former highflier filled with potential, now sits more than 80% lower than its 52-week peak. Sales of revolutionary prostate cancer vaccine Provenge have shown slowing growth after a ballyhooed launch. With shares beaten down, positive guidance from management could cause a pop; otherwise, it could be more disappointment for investors.
The prostate cancer treatment revolution is not the only game in town for investors. For a good way to play the tech revolution, The Motley Fool has just released a free report on mobile named "The Next Trillion-Dollar Revolution" that details a hidden component play inside mobile phones that also is a market leader in the exploding Chinese market. Inside the report, we not only describe why the mobile revolution will dwarf any other technology revolution seen before it, but we also name the company at the forefront of the trend. Hundreds of thousands have requested access to previous reports, and you can access this new report today by clicking here -- it's free.
The article Another Dendreon Earnings Disaster? originally appeared on Fool.com.David Williamson owns shares of Johnson & Johnson and Dendreon, but he holds no other position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson and Dendreon. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and creating a diagonal call position in Johnson & Johnson. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.